Equity Overview
Price & Market Data
Price: $3.34
Daily Change: $0.00 / 0.00%
Daily Range: $2.86 - $3.35
Market Cap: $434,551,264
Daily Volume: 3,286,982
Performance Metrics
1 Week: 4.37%
1 Month: -21.78%
3 Months: -7.48%
6 Months: -13.70%
1 Year: -30.13%
YTD: -7.48%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.